Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging by Varela Ignacio, Pereira Sandrine, Ugalde Alejandro P, Navarro Claire L, Suárez María F, Cau Pierre, Cadiñanos Juan, Osorio Fernando G, Foray Nicolas, Cobo Juan, de Carlos Félix, Lévy Nicolas, Freije José M P, López-Otín Carlos in Nature medicine (2008).

[PMID: 18587406] PubMed


Several human progerias, including Hutchinson-Gilford progeria syndrome (HGPS), are caused by the accumulation at the nuclear envelope of farnesylated forms of truncated prelamin A, a protein that is also altered during normal aging. Previous studies in cells from individuals with HGPS have shown that farnesyltransferase inhibitors (FTIs) improve nuclear abnormalities associated with prelamin A accumulation, suggesting that these compounds could represent a therapeutic approach for this devastating progeroid syndrome. We show herein that both prelamin A and its truncated form progerin/LADelta50 undergo alternative prenylation by geranylgeranyltransferase in the setting of farnesyltransferase inhibition, which could explain the low efficiency of FTIs in ameliorating the phenotypes of progeroid mouse models. We also show that a combination of statins and aminobisphosphonates efficiently inhibits both farnesylation and geranylgeranylation of progerin and prelamin A and markedly improves the aging-like phenotypes of mice deficient in the metalloproteinase Zmpste24, including growth retardation, loss of weight, lipodystrophy, hair loss and bone defects. Likewise, the longevity of these mice is substantially extended. These findings open a new therapeutic approach for human progeroid syndromes associated with nuclear-envelope abnormalities.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.